Welcome to our dedicated page for Amedisys news (Ticker: AMED), a resource for investors and traders seeking the latest updates and insights on Amedisys stock.
Amedisys, Inc. (NASDAQ: AMED) is a healthcare at home company that reports on developments across home health, hospice and high acuity care services delivered in the home. The Amedisys news flow includes regular earnings announcements, corporate updates and clinical program disclosures that reflect its role in the home health care services industry.
Investors and observers following AMED news can expect detailed quarterly and annual financial results, including net service revenue, net income, adjusted EBITDA and other non-GAAP measures that Amedisys reconciles to GAAP in its releases. These earnings communications often discuss factors such as merger-related expenses, impairment charges and other items that affect reported and adjusted results.
Amedisys also issues news about its clinical initiatives and partnerships. For example, the company has announced the rollout of advanced molecular testing for infection diagnosis in collaboration with Patient Choice Laboratories, aimed at improving the speed and accuracy of identifying pathogens in urine, respiratory and wound infections in the home setting. Through its subsidiary Contessa Health, Amedisys has highlighted participation in models such as the Centers for Medicare & Medicaid Services’ GUIDE Model for dementia care, reflecting activity in alternative payment and care delivery models.
Other Amedisys news items cover recognition for patient and caregiver satisfaction, such as SHPBest™ awards for home health and hospice care centers, and updates related to its merger with UnitedHealth Group, including regulatory and legal milestones. Readers who monitor AMED news gain insight into the company’s financial performance, regulatory environment, care quality indicators and the evolution of its home-based service offerings.
Amedisys (NASDAQ: AMED) announces a collaboration with Option Care Health (NASDAQ: OPCH) to provide COVID antibody infusion therapy in long-term care facilities. The pilot program, starting in Indianapolis and Valparaiso, Indiana, aims to enhance access to vital therapies for high-risk COVID-19 patients. Amedisys will manage care coordination, while Option Care Health will oversee clinical pharmacy operations and distribute Bamlanivimab. This partnership reflects both companies' commitment to addressing critical healthcare challenges during the pandemic.
Amedisys, a top home health and hospice provider, announced that CEO Paul B. Kusserow will present at the 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021, at 3:40 p.m. ET. Investors can access the live webcast via the company’s website. Amedisys delivers personalized healthcare at home, serving over 415,000 patients annually through a network of 516 care centers across 39 states and D.C. With a strong focus on patient-centered care, it partners with more than 2,600 hospitals and 67,000 physicians nationwide.
Amedisys, Inc. (NASDAQ: AMED) has authorized a stock repurchase program allowing the company to buy back up to $100 million of its common stock by December 31, 2021. CFO Scott Ginn noted the decision reflects the company's strong cash flow and low leverage, emphasizing that share buybacks will be part of their capital deployment strategy, alongside priority on acquisitions in Home Health and Hospice. Repurchases may occur through various methods, depending on market conditions and legal requirements.
Amedisys has appointed Ivanetta Davis Samuels to its Board of Directors, effective December 15, 2020. Samuels brings over 25 years of legal expertise from her role as Senior Vice President and General Counsel at Meharry Medical College. Amedisys CEO Paul Kusserow emphasizes her experience will enhance the company's leadership as it seeks to provide quality care for aging patients. Samuels expressed her excitement about joining a board predominantly composed of women and supporting equitable healthcare.
Amedisys, Inc. (NASDAQ: AMED) announced that CEO Paul B. Kusserow will present at the Jefferies Virtual London Healthcare Conference on November 17, 2020, starting at 9:25 a.m. Eastern Time. The presentation will be accessible via live webcast on Amedisys' investor relations website. Amedisys is a leading provider of home health, hospice, and personal care services, serving over 415,000 patients annually through 516 care centers across 39 states and D.C. The company is committed to delivering high-quality healthcare at home.
Amedisys, a leader in home health, hospice, and personal care, announces that CEO Paul B. Kusserow will present at the Stephens Annual Investment Conference on November 19, 2020, at 2:00 p.m. ET. Investors can access the live webcast via the Amedisys website. Founded in 1982 and headquartered in Baton Rouge, LA, Amedisys operates over 500 care centers across 39 states and serves more than 415,000 patients annually, partnering with over 2,600 hospitals and 67,000 physicians nationwide.
Amedisys, Inc. (NASDAQ: AMED), a top provider of home health, hospice, and personal care services, announced that CEO Paul B. Kusserow will present at the 29th Annual Credit Suisse Virtual Healthcare Conference on November 10, 2020, at 2:00 p.m. Eastern Time. The presentation will be available via live webcast on the Amedisys website. Established in 1982 and headquartered in Baton Rouge, LA, Amedisys serves over 415,000 patients annually through its 516 care centers across 39 states and the District of Columbia, employing 21,000 staff dedicated to quality care.
Amedisys, Inc. (NASDAQ: AMED) reported significant growth for Q3 2020, with net service revenue increasing by $49.5 million to $544.1 million compared to Q3 2019. Net income rose to $72.0 million ($2.16 per diluted share), aided by a $0.72 income tax benefit. Year-to-date results also showed a revenue increase of $65.9 million, totaling $1.520 billion, and net income of $138.5 million ($4.16 per diluted share). The company raised its full-year revenue guidance to $2.067-$2.072 billion and adjusted EBITDA forecast to $269-$272 million, asserting strong performance despite COVID-19 challenges.
Amedisys, Inc. (NASDAQ: AMED) will disclose its third-quarter financial results on October 28, 2020, after the market closes. An investor conference call is scheduled for October 29, 2020, at 11:00 a.m. ET to discuss these results. Interested participants can join by calling (877) 524-8416 (Toll-Free) or (412) 902-1028 (Toll). A replay will be available until November 29, 2020. Amedisys offers personalized home health care and hospice services, serving over 415,000 patients annually through more than 21,000 employees across 39 states.
Amedisys, a leading home health, hospice, and personal care company, will have its CEO, Paul B. Kusserow, present at the Baird 2020 Global Healthcare Conference on September 10, 2020, at 1:25 p.m. Eastern Time. Investors can access a live webcast of the presentation through the Amedisys investor relations website. Amedisys, founded in 1982 and headquartered in Baton Rouge, LA, provides personalized care to over 415,000 patients annually through its extensive network of 524 care centers across 39 states.
FAQ
What is the current stock price of Amedisys (AMED)?
What is the market cap of Amedisys (AMED)?
